Patient
Subtyping
Mammatyper is designed specifically to measure these 4 biomarkers
The 17th St Gallen International breast cancer Conference (2021) Expert Panel recommends the use of four biomarkers for molecular subtyping of breast cancer:
HER2
ER
PR
Ki-67
- ERBB2 (HER2, human epidermal growth factor receptor 2)
- ESR1 (estrogen receptor 1)
- PGR (progesterone receptor)
- MKI67 (marker of proliferation Ki-67, a marker expressed in proliferating cells)
These markers, in turn, are used to
identify 5 distinct breast cancer
subtypes:
- Luminal A-like
- Luminal B-like (HER2 negative)
- Luminal B-like (HER2 positive)
- HER2 positive (non-luminal)
- Triple negative (ductal)
Each of these subtypes is associated with a clear therapy recommendation and distinct characteristics of the patient’s prognosis.